title: Drug firms back-pedal on direct advertising.
mesh_terms: D000329:Advertising / Q000191:economics / Q000331:legislation & jurisprudence* / Q000592:standards*; D004345:Drug Industry / Q000191:economics* / Q000331:legislation & jurisprudence*; D017408:Guidelines as Topic / Q000592:standards*; D006801:Humans; D007093:Imidazoles / Q000191:economics; D007783:Lactones / Q000009:adverse effects; D010879:Piperazines / Q000191:economics; D013450:Sulfones / Q000009:adverse effects / Q000191:economics; D013690:Television / Q000191:economics / Q000331:legislation & jurisprudence; D014227:Triazines / Q000191:economics; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence; D000069058:Vardenafil Dihydrochloride
chemical_list: D007093:Imidazoles; D007783:Lactones; D010879:Piperazines; D013450:Sulfones; D014227:Triazines; C116926:rofecoxib; D000069058:Vardenafil Dihydrochloride